128 related articles for article (PubMed ID: 9300138)
1. A predictive model for area under the concentration versus time curve of cyclosporin A using several routine monitoring results in renal transplant patients.
Shibata N; Hayakawa T; Hoshino N; Minouchi T; Yamaji A
Biol Pharm Bull; 1997 Aug; 20(8):897-903. PubMed ID: 9300138
[TBL] [Abstract][Full Text] [Related]
2. Relationship between area under the concentration versus time curve of cyclosporin A, creatinine clearance, hematocrit value, and other clinical factors in Japanese renal transplant patients.
Shibata N; Hoshino N; Minouchi T; Yamaji A; Park K; Tomoyoshi T; Abe H; Kodama M
Int J Clin Pharmacol Ther; 1998 Apr; 36(4):202-9. PubMed ID: 9587046
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
Schädeli F; Marti HP; Frey FJ; Uehlinger DE
Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
[TBL] [Abstract][Full Text] [Related]
4. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation.
Mahalati K; Belitsky P; Sketris I; West K; Panek R
Transplantation; 1999 Jul; 68(1):55-62. PubMed ID: 10428267
[TBL] [Abstract][Full Text] [Related]
5. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
6. The area under the concentration-time curve versus trough and peak blood level monitoring in renal transplant recipients on cyclosporine.
Halim MA; Nampoory MR; Johny KV; Donia F; Hamid MH; Said T; Nair MP; Mansour M; Al-Muzairai I; Samhan M; Al-Mousawi M
Transplant Proc; 2005 Sep; 37(7):3019-21. PubMed ID: 16213291
[TBL] [Abstract][Full Text] [Related]
7. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
Bunnag S; Vareesangthip K; Ong-ajyooth L
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
[TBL] [Abstract][Full Text] [Related]
8. Comparative pharmacokinetics and renal effects of cyclosporin A and cyclosporin G in renal allograft recipients.
Gruber SA; Gallichio M; Rosano TG; Kaplan SS; Hughes SE; Urbauer DL; Singh TP; Lempert N; Conti DJ; Stein DS; Drusano G
J Clin Pharmacol; 1997 Jul; 37(7):575-86. PubMed ID: 9243350
[TBL] [Abstract][Full Text] [Related]
9. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
10. Limited sampling strategy for cyclosporine (Neoral) area under the curve monitoring in pediatric kidney transplant recipients.
Strong DK; Lai A; Primmett D; White CT; Lirenman DS; Carter JE; Hurley RM; Virji M; Ensom MH
Pediatr Transplant; 2005 Oct; 9(5):566-73. PubMed ID: 16176411
[TBL] [Abstract][Full Text] [Related]
11. Comparison of several approaches of therapeutic drug monitoring of cyclosporin A based on individual pharmacokinetics.
Wacke R; Rohde B; Engel G; Kundt G; Hehl EM; Bast R; Seiter H; Drewelow B
Eur J Clin Pharmacol; 2000 Apr; 56(1):43-8. PubMed ID: 10853876
[TBL] [Abstract][Full Text] [Related]
12. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
[TBL] [Abstract][Full Text] [Related]
13. A strategy to calculate cyclosporin A area under the time-concentration curve in pediatric renal transplantation.
David-Neto E; Araujo LP; Feres Alves C; Sumita N; Romano P; Yagyu EM; Nahas WC; Ianhez LE
Pediatr Transplant; 2002 Aug; 6(4):313-8. PubMed ID: 12234272
[TBL] [Abstract][Full Text] [Related]
14. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
[TBL] [Abstract][Full Text] [Related]
15. Impact of the variability of cyclosporin A trough levels on long-term renal allograft function.
Waiser J; Slowinski T; Brinker-Paschke A; Budde K; Schreiber M; Böhler T; Hauser I; Neumayer HH
Nephrol Dial Transplant; 2002 Jul; 17(7):1310-7. PubMed ID: 12105257
[TBL] [Abstract][Full Text] [Related]
16. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant.
Pawinski T; Durlik M; Szlaska I; Urbanowicz A; Majchrnak J; Gralak B
J Clin Pharm Ther; 2006 Feb; 31(1):27-34. PubMed ID: 16476117
[TBL] [Abstract][Full Text] [Related]
17. Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation.
Cortinovis M; Gotti E; Pradini S; Gaspari F; Perico N
Transplantation; 2011 Sep; 92(5):550-6. PubMed ID: 21709602
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study and limited sampling strategy of cyclosporine in Japanese heart transplant recipients.
Wada K; Takada M; Ueda T; Ochi H; Morishita H; Hanatani A; Nakatani T
Circ J; 2006 Oct; 70(10):1307-11. PubMed ID: 16998264
[TBL] [Abstract][Full Text] [Related]
19. Improving the therapeutic monitoring of cyclosporin A.
Warrens AN; Waters JB; Salama AD; Lechler RI
Clin Transplant; 1999 Apr; 13(2):193-200. PubMed ID: 10202617
[TBL] [Abstract][Full Text] [Related]
20. Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population.
Potter JM; McWhinney BC; Sampson L; Hickman PE
Ther Drug Monit; 2004 Aug; 26(4):408-14. PubMed ID: 15257071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
